C5a Receptor Expression in Circulating Myeloid Cells in ARDS Secondary to COVID-19
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 2
- 主要终点
- Show an overexpression of C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers).
研究概览
简要总结
The pathophysiology of ARDS is linked to an uncontrolled inflammatory response at the level of alveolo-capillary membrane, mediated by neutrophils and mononuclear cells. The complement system and anaphylatoxin C5a have shown central role in the recruitment of these pro-inflammatory cells and more broadly in the genesis of cytokinic storm syndrome. C5a acts via receptors C5aR and C5L2.
This is a preliminary study aimed at studying the expression of the C5a receptor on myeloid cells in peripheral blood of patients with ARDS secondary to COVID-19.
This study has of primary objective to show there is an overexpression of the C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers).
The medium-term objective is to develop a clinical trial to test the effectiveness of anti-C5aR antibody in this condition.
详细描述
The pathophysiology of ARDS is linked to an uncontrolled inflammatory response at the level of alveolo-capillary membrane, mediated by neutrophils and mononuclear cells. The complement system and anaphylatoxin C5a have shown central role in the recruitment of these pro-inflammatory cells and more broadly in the genesis of cytokinic storm syndrome. C5a acts via receptors C5aR and C5L2.
This is a preliminary study aimed at studying the expression of the C5a receptor on myeloid cells in peripheral blood of patients with ARDS secondary to COVID-19.
This study has of primary objective to show there is an overexpression of the C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers).
The medium-term objective is to develop a clinical trial to test the effectiveness of anti-C5aR antibody in this condition.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For patients in resuscitation unit with ARDS linked to COVID-19:
- •Patient under invasive mechanical ventilation
- •PaO2 / FiO2 <300
- •PCR SARS-CoV-2 positive in a pharyngeal or respiratory sample
- •For control patients with COVID-19 without ARDS
- •Oxygen flow always less than 5 L / min
- •PCR SARS-CoV-2 positive in a pharyngeal or respiratory sample
- •No passage in resuscitation unit
- •Favorable evolution
排除标准
- •Patient deprived of liberty
- •Patient's refusal to participate at study
- •Patient for whom therapeutic limitation measures such as non-admission to intensive care have been issued
- •Medullar aplasia
结局指标
主要结局
Show an overexpression of C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers).
时间窗: 72 hours
The endpoint is the expression of the C5a receptor (C5aR) in peripheral blood myeloid cells, expressed as a percentage of cells expressing C5a receptor and as median fluorescence intensity (MFI), during the first 72 hours of patient management in resuscitation unit.
次要结局
未报告次要终点